BOOKS BY CATEGORY
Your Account
Antisense–Based Drugs and Therapeutics
Preclinical and Clinical Considerations for Development
This book is currently unavailable – please contact us for further information.
Price
Quantity
€142.74
(To see other currencies, click on price)
Hardback
Add to basket  

MORE ABOUT THIS BOOK

Main description:

Antisense–based drugs are part of a growing number of pharmaceutical and biotech programs to treat diseases including cancer, diabetes, and ALS. Reviewing fundamentals and offering guidelines for drug discovery and development, this book is a practical guide from the safety assessment to clinical experience with antisense oligonucleotides.


 Examines principles and tools for scientists in both pre–clinical and clinical settings and how to apply them to antisense oligonucleotides
 Reviews fundamentals and provides guidelines for scientists in drug design and discovery to increase efficiency, assessment, and success of drug candidates
 Helps readers understand antisense molecules and their targets, biochemistry and toxicity mechanisms, roles in disease, and applications for safety and therapeutics
 Includes interdisciplinary perspectives, from both academia and research, on a hot topic that combines pharmacology, toxicology, biology, and medicinal chemistry to advance our understanding and application of therapeutics


PRODUCT DETAILS

ISBN-13: 9781118537336
Publisher: John Wiley & Sons Ltd (Wiley–Blackwell)
Publication date: November, 2016
Pages: 576
Weight: 652g
Availability: Not available (reason unspecified)
Subcategories: Diseases and Disorders

MEET THE AUTHOR

Nicolay Ferrari, PhD, is a Lecturer in the Department of Pharmacology at the University of Sherbrooke, Quebec, Canada. Previously, he was the Director of Research in Pharmacology at Topigen Pharmaceuticals, Inc. With 18 years of research experience and 10 years of experience in academia and the biotechnology industry, Dr. Ferrari is the co–inventor of 6 patents and author of numerous articles and book chapters.

Rosanne Seguin, PhD,
is an Academic Associate at the Montreal Neurological Institute of McGill University, Quebec, Canada. Previously, she was a Consultant and the Director of Immunology and Development Support at Topigen Pharmaceuticals, Inc. Dr. Seguin has 20 years of research experience with 9 years of experience in the biotechnology/pharmaceutical industry.

CUSTOMER REVIEWS

Average Rating